Misadventures of promotions in the Pharmaceutical industry

A recent research by Mulinari et al (2015) suggests that UK’s self-regulatory system which is controlled by the PMCPA, who are responsible for detecting and sanctioning pharmaceutical companies, who break marketing regulations by promoting drugs off-label should be reformed. Mulinari et al (2015) carried out a qualitative analysis of data gathered between 2004-2012 from constitutions in the UK and Sweden. This data included information regarding rulings and complaints. The researchers found that in Sweden, 47% of complaints came from active monitoring, whilst in the UK only 0.2%. Now, this begs the question, are we doing less to regulate off-label promotion in the UK. The article also highlights that the majority of the violation relates to complaints regarding people who felt misled by a promotion. The article highlights, that the charges incurred by these violations, accounted for 0.014% (Sweden) and 0.0051% (UK) of annual sales revenues.  A few examples of serious areas of violations pertained to diabetes drugs in the UK and Urologics in Sweden, the article included the following:

  1. pre-licensing
  2. promotion of prescription drugs to the public
  3. off-label promotion

Mulinari et al (2015) concluded by stating, that ‘the prevalence and severity of breaches testifies to a discrepancy between the ethical standard codified in industry Codes of Conduct and the actual conduct of the industry’. Therefore, they proposed pre-vetting, intensified active monitoring, larger fines and greater publicity to rulings.

I personally feel that patient care should be paramount, and core to all acts within the pharmaceutical industry.  However, Mulinari (2015) findings suggest a need for tightening the processes in the industry. However, care should be taken, not to indirectly have a negative impact on patient care. Finally, the data was gathered from 2004-2012, a lot has changed since then, the ABPI code has been revised. And, the industry has learnt from the huge fines, and recent regulations levied against it (i.e. transparency rules).

If you are interested in protecting your brand, please read Copy Approval – A quick guide to protecting your brand image

 

Created by A.Tojuola MPharmS

12573859_941090242634383_2800272836521046385_n

Reference

Zetterqvist, Anna V., Juan Merlo, and Shai Mulinari. “Complaints, Complainants, And Rulings Regarding Drug Promotion In The United Kingdom And Sweden 2004–2012: A Quantitative And Qualitative Study Of Pharmaceutical Industry Self-Regulation”. PLoS Med 12.2 (2015): e1001785. Web. 7 Feb. 2016.

Leave a Comment